Trial Profile
Impact of pre-existent resistance on maintenance of virological suppression in antiretroviral treated HIV-1 suppressed patients switched to tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) single-tablet regimen
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2016
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 20 Dec 2016 Results published in the Journal of Antimicrobial Chemotherapy
- 02 Mar 2016 New trial record